StreetInsider.com News Articles

NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions

Wed, 03 Jun 2026 08:00:00 -0400

NAARDEN, The Netherlands and MIAMI, June 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the National Lipid Association (NLA) 2026 Scientific Sessions, taking place on June 11 – 14, 2026 in Chicago, Illinois.

Presentation details

NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions

Wed, 03 Jun 2026 08:00:00 -0400

Presentation details

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

Thu, 28 May 2026 08:00:00 -0400

NAARDEN, the Netherlands and MIAMI, May 28, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:

Jefferies Global Healthcare Conference 2026 in New York, NY on Wednesday, June 3, 2026. Michael Davidson, M.D., Chief Executive Officer, and Matthew Philippe, Executive Vice President, Head

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

Thu, 28 May 2026 08:00:00 -0400

Jefferies Global Healthcare Conference 2026 in New York, NY on Wednesday, June 3, 2026. Michael Davidson, M.D., Chief Executive Officer, and Matthew Philippe, Executive Vice President, Head

Form 4 NewAmsterdam Pharma Co For: May 26 Filed by: Kooij Louise Frederika

Wed, 27 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260527/26558390.html

Form 4 NewAmsterdam Pharma Co For: May 26 Filed by: Kooij Louise Frederika

Wed, 27 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260527/26558390.html

Piper Sandler's Thoughts on NewAmsterdam Pharma Co NV (NAMS) Post Investor Dinner

Tue, 12 May 2026 08:11:13 -0400

Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $60.00 price target on NewAmsterdam Pharma Co NV (NASDAQ: NAMS).

The analyst commented: "We hosted NAMS for an investor dinner in NYC to discuss their recent announcement of an interim analysis in 4Q26 (result 1Q27) for obicetrapib's Ph3 PREVAIL outcomes study. Importantly, this decision was driven by a highly encouraging event decay rate observed across all components of MACE in Year 2 which mgmt believes is driven by obicetrapib's effect on outcomes. As such, the interim analysis enables NAMS two shots on goal where mgmt is optimistic the study may be

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May